{"id":"placebo-for-rosuvastatin-10mg","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL1744447","moleculeType":"Small molecule","molecularWeight":"1001.15"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"As a placebo, it serves as a control in clinical trials to compare the efficacy of the active drug, Rosuvastatin 10mg, without any actual therapeutic effect.","oneSentence":"Placebo does not have a pharmacological effect.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:21.060Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control in clinical trials for cardiovascular diseases"}]},"trialDetails":[{"nctId":"NCT06981299","phase":"PHASE1","title":"A Phase 1 Study of PROT-001.","status":"COMPLETED","sponsor":"Protego Biopharma Pty Ltd","startDate":"2025-05-29","conditions":"Healthy","enrollment":102},{"nctId":"NCT06317051","phase":"PHASE3","title":"Optimising Metabolic Management for People With Human Immunodeficiency Virus (HIV) on Integrase Based Antiretroviral Therapy (ART)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kirby Institute","startDate":"2024-12-16","conditions":"HIV Infections, Weight Gain","enrollment":300},{"nctId":"NCT04542382","phase":"PHASE1","title":"Identification and Validation of Biomarkers for Breast Cancer Resistance Protein (BCRP)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2021-10-28","conditions":"Healthy Volunteers","enrollment":11},{"nctId":"NCT06036784","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study of MBX 1416 in Healthy Subjects","status":"COMPLETED","sponsor":"MBX Biosciences","startDate":"2023-09-18","conditions":"Postbariatric Hypoglycemia","enrollment":69},{"nctId":"NCT02008786","phase":"PHASE4","title":"Statin and Angiotensin-converting Enzyme Inhibitor on Symptoms in Patients With SCAD","status":"TERMINATED","sponsor":"Cardiology Research UBC","startDate":"2014-06","conditions":"Coronary Artery Dissection, Spontaneous","enrollment":18},{"nctId":"NCT03113994","phase":"PHASE2","title":"Statin Monotherapy for Treatment of Endocrine Metabolic Disease Risk","status":"UNKNOWN","sponsor":"Dr. B. Catharine. Craven","startDate":"2018-02-26","conditions":"Spinal Cord Injuries, Osteoporosis, Metabolic Syndrome","enrollment":8},{"nctId":"NCT02977065","phase":"PHASE2","title":"To Assess the Safety, Efficacy and Tolerability of CKD-519, Administered With HMG-CoA Reductase Inhibitors","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2017-03-23","conditions":"Dyslipidemias","enrollment":62},{"nctId":"NCT00979121","phase":"PHASE3","title":"Statins for Acutely Injured Lungs From Sepsis","status":"TERMINATED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2010-01","conditions":"Sepsis, Acute Lung Injury","enrollment":745},{"nctId":"NCT02445352","phase":"PHASE3","title":"Efficacy/Safety of DP-R207 Tablet Versus CRESTOR Tablet in Patients With Primary Hypercholesterolemia","status":"COMPLETED","sponsor":"Alvogen Korea","startDate":"2014-07","conditions":"Primary Hypercholesterolemia","enrollment":379},{"nctId":"NCT02087540","phase":"PHASE3","title":"Efficacy and Safety of Telmisartan/Rosuvastatin Co-administration in Hypertensive Patients With Hyperlipidemia","status":"UNKNOWN","sponsor":"IlDong Pharmaceutical Co Ltd","startDate":"2013-05","conditions":"Hypertension, Hyperlipidemia","enrollment":310},{"nctId":"NCT00555230","phase":"PHASE2","title":"Effects of HMG-coA Reductase Inhibitor on Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2007-07","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT01245803","phase":"PHASE4","title":"Acute Rosuvastatin for Preventing Myocardial Damage in Patients With ACS","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2010-04","conditions":"Acute Coronary Syndrome, Angioplasty","enrollment":400},{"nctId":"NCT00371501","phase":"PHASE4","title":"Aspirin and Statins for Prevention of Atherosclerosis and Arterial Thromboembolism in Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2006-06","conditions":"Atherosclerosis, Thromboembolism, Systemic Lupus Erythematosus","enrollment":72}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo(for Rosuvastatin 10mg)","genericName":"Placebo(for Rosuvastatin 10mg)","companyName":"IlDong Pharmaceutical Co Ltd","companyId":"ildong-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Placebo does not have a pharmacological effect. Used for Control in clinical trials for cardiovascular diseases.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}